Radiopharm Theranostics Ltd
RADX · XNASCIK 1949257fmd_0CTY5B4NBYMSDYZTQTV72NZF1ZManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jul 01, 2022 to Jun 30, 2026, 4 periods
Loading
Latest annual · FY2025
Millions- Total revenues
- 4
- Gross profit
- 0
- Operating income
- (38)
- Net income
- (38)
Radiopharm Theranostics Ltd (RADX) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $3.6 million | $299,228 | +1,114.3% | 20-F 2025-09-18 · proof |
| Gross profit | $39,276 | $299,228 | -86.9% | 20-F 2025-09-18 · proof |
| Operating income | -$38.2 million | -$47.2 million | 20-F 2025-09-18 · proof | |
| Net income | -$38.3 million | -$47.9 million | 20-F 2025-09-18 · proof | |
| Cash from operating activities | -$36.6 million | -$23 million | 20-F 2025-09-18 · proof | |
| Total assets | $86.5 million | $72 million | +20.1% | 20-F 2025-09-18 · proof |
| Total liabilities | $43.6 million | $44.7 million | -2.4% | 20-F 2025-09-18 · proof |
| Cash and cash equivalents | $29.1 million | $18.6 million | +56.8% | 20-F 2025-09-18 · proof |
- What was Radiopharm Theranostics Ltd (RADX)'s revenue in fiscal 2025?
- Radiopharm Theranostics Ltd (RADX) reported revenue of $3.6 million for fiscal 2025 (the year ended Jun 30, 2025), against $299,228 the year before (+1,114.3%). Source: the 20-F filed with the SEC on Sep 18, 2025. SEC
- What was Radiopharm Theranostics Ltd (RADX)'s gross profit in fiscal 2025?
- Radiopharm Theranostics Ltd (RADX) reported gross profit of $39,276 for fiscal 2025 (the year ended Jun 30, 2025), against $299,228 the year before (-86.9%). Source: the 20-F filed with the SEC on Sep 18, 2025. SEC
- What was Radiopharm Theranostics Ltd (RADX)'s operating income in fiscal 2025?
- Radiopharm Theranostics Ltd (RADX) reported operating income of -$38.2 million for fiscal 2025 (the year ended Jun 30, 2025), against -$47.2 million the year before. Source: the 20-F filed with the SEC on Sep 18, 2025. SEC
- What was Radiopharm Theranostics Ltd (RADX)'s net income in fiscal 2025?
- Radiopharm Theranostics Ltd (RADX) reported net income of -$38.3 million for fiscal 2025 (the year ended Jun 30, 2025), against -$47.9 million the year before. Source: the 20-F filed with the SEC on Sep 18, 2025. SEC
- What was Radiopharm Theranostics Ltd (RADX)'s cash from operating activities in fiscal 2025?
- Radiopharm Theranostics Ltd (RADX) reported cash from operating activities of -$36.6 million for fiscal 2025 (the year ended Jun 30, 2025), against -$23 million the year before. Source: the 20-F filed with the SEC on Sep 18, 2025. SEC
- What are Radiopharm Theranostics Ltd (RADX)'s total assets?
- As of Jun 30, 2025, Radiopharm Theranostics Ltd (RADX) reported total assets of $86.5 million, against $72 million a year earlier (+20.1%). Source: the 20-F filed with the SEC on Sep 18, 2025. SEC
- What are Radiopharm Theranostics Ltd (RADX)'s total liabilities?
- As of Jun 30, 2025, Radiopharm Theranostics Ltd (RADX) reported total liabilities of $43.6 million, against $44.7 million a year earlier (-2.4%). Source: the 20-F filed with the SEC on Sep 18, 2025. SEC
- What are Radiopharm Theranostics Ltd (RADX)'s cash and cash equivalents?
- As of Jun 30, 2025, Radiopharm Theranostics Ltd (RADX) reported cash and cash equivalents of $29.1 million, against $18.6 million a year earlier (+56.8%). Source: the 20-F filed with the SEC on Sep 18, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:RADX&period_type=annual&limit=5"Information only, not investment advice.